News Search Results

Displaying Results 126-150 of 644 "ophthalmology"

Jun 30, 2026, 09:00 ET LensCrafters Enters a New Era of Med-Tech Innovation, Building an Integrated Ecosystem of Care

treatments and procedures inside of the LensCrafters Vision & Eye Health Center  is owned and operated by Friendly Eyes Vision PLLC. The doctor of ophthalmology performing surgery and other medical treatments and procedures at the LensCrafters Vision & Eye Health Center provides services on behalf of

More news about: LensCrafters


Jun 30, 2026, 08:45 ET Outcomes Matter Innovations (OMI) Welcomes Healthcare Industry Leader Steve Wiggins as Board Observer

technology—areas directly aligned with OMI's work to improve outcomes and reduce unnecessary variation in high‑cost clinical areas such as oncology, ophthalmology, and chronic disease management."OMI is solving one of the most important challenges in healthcare: how to deliver predictable, evidence‑aligned,

More news about: Outcomes Matter Innovations, LLC


Jun 30, 2026, 08:00 ET Virtual Vision Health Surpasses 2.5 Million Exams and 1 Million Patients Worldwide

platform across ophthalmology, optometry, academic institutions, and healthcare organizations seeking more accessible, efficient, and patient-centered approaches to vision care.The announcement follows new research presented at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual

More news about: Virtual Vision Health


Jun 30, 2026, 00:00 ET Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion

More news about: Innovent Biologics


Jun 29, 2026, 10:01 ET Therapeutic Contact Lenses Market to Reach USD 35.2 Billion by 2036 Driven by Advanced Corneal Care, Drug Delivery Innovation, and Expanding Ophthalmic Procedures

depend on advancements in silicone hydrogel materials, extended-wear safety, clinical validation, and stronger collaborations between manufacturers, ophthalmology clinics, and hospital networks to improve patient outcomes and treatment adherence.Get detailed market forecasts, competitive benchmarking,

More news about: Future Market Insights


Jun 29, 2026, 07:05 ET REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

2010;376(9735):124–36.3 Lundeen EA, Burke-Conte Z, Rein DB, Wittenborn JS, Saaddine J, Lee AY, Flaxman AD. Prevalence of Diabetic Retinopathy in the US in 2021. JAMA Ophthalmology. 2023;141(8):747-754.4 Berrocal MD, Alexandra Acabá. Current Management of Diabetic Retinopathy, 2018

More news about: REGENXBIO Inc.


Jun 26, 2026, 06:16 ET Artelus wins Roche Drishti HealthTech Challenge

years, Roche has been dedicated to improving lives in India, evolving from Vitamins in the 1940s to advanced, differentiated medicines for cancer, ophthalmology, neurology and blood disorders. For more information, visit www.rocheindia.comPhoto:

More news about: Roche Products (India) Pvt. Ltd.


Jun 25, 2026, 12:20 ET Parker Waichman LLP Files Lawsuit on behalf of Ohio Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic

concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering

More news about: Parker Waichman LLP


Jun 24, 2026, 20:00 ET Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026

that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin has completed an oversubscribed $330 million Series B financing.

More news about: Innovent Biologics


Jun 24, 2026, 10:15 ET JULY DECLARED AS DRY EYE MONTH BY PREVENT BLINDNESS TO PROVIDE PUBLIC AND ALLIED HEALTHCARE PROFESSIONALS WITH NO-COST EDUCATIONAL RESOURCES ON DRY EYE

Dry Eye" with Prevent Blindness Board of Directors Member Stephanie Jones Marioneaux, MD, President-Elect of the American Academy of Ophthalmology (AAO).Symptoms of dry eye include:Fluctuating blurry visionBurning or stingingParticles in

More news about: Prevent Blindness


Jun 24, 2026, 08:40 ET InMode Confirms Receipt of Unsolicited Proposal

technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology and ophthalmology.  For more information about the Company and its wide array of medical technologies, visit www.inmodemd.com.

More news about: InMode LTD


Jun 24, 2026, 08:00 ET New Report - Voice AI in Specialty Patient Access: How Specialty Leaders Should Evaluate Solutions, Avoid Pitfalls, and Select the Right Partner

Solutions, Avoid Pitfalls, and Select the Right Partner." The report draws on in-depth interviews with specialty group leaders across dermatology, ophthalmology, orthopedics and multispecialty organizations.

More news about: Artera


Jun 23, 2026, 23:39 ET Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026

highlighted several global innovative drug pipelines, encompassing GB18 for cancer cachexia, GB19/GB26 for systemic lupus erythematosus, GB10 for ophthalmology, and GB20/GB24 for autoimmune disorders. In addition, the clinical progress for two Phase III programs—long-acting GC and GB05 (interferon inhalation

More news about: Kexing Biopharm


Jun 23, 2026, 11:23 ET WPI Expands NanoFil™ Family with New Syringe Sizes for Ultra-Low-Volume Delivery

NanoFil™ syringes provide researchers with greater flexibility, improved dosing resolution, and enhanced control for key research applications such ophthalmology and neuroscience. These offerings are expected to be available early this summer.SARASOTA, Fla.,

More news about: World Precision Instruments, Inc.


Jun 23, 2026, 10:25 ET Ophthalmic Drugs Market Outlook 2026-2031: Over 8% CAGR Projected as Advancements in Ocular Therapeutics Drive Growth, Says Mordor Intelligence

Drugs Market Competitive OutlookThe ophthalmic drugs market features global pharmaceutical companies, biotechnology firms, and specialty ophthalmology-focused organizations competing through innovation, product development, and strategic collaborations. Market participants are investing in biologics,

More news about: Mordor Intelligence Private Limited


Jun 23, 2026, 09:00 ET Century Health and Arizona Gastrointestinal Associates Partner to Accelerate Real-World Evidence in IBD and MASH

research-grade datasets with accuracy validated against clinical expert judgment. Spanning therapeutic areas including neurology, immunology, and ophthalmology, the company's proprietary specialty provider network covers more than 200 sites and 500,000 longitudinal patient records across 12 disease areas.

More news about: Century Health


Jun 22, 2026, 04:57 ET Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits

associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics

More news about: Piramal Pharma Solutions


Jun 22, 2026, 04:46 ET Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits

associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics

More news about: Piramal Pharma Solutions


Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma

that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed

More news about: Innovent Biologics


Jun 18, 2026, 13:54 ET The Inner Circle acknowledges Evelyn A. Paysse, MD as a 3 Year Pinnacle

School of Medicine. She completed her residency in ophthalmology at the University of Southern California Doheny Eye Institute, followed by a fellowship in pediatric ophthalmology at Indiana University. Dr. Paysse is board certified in ophthalmology.Dr. Paysse maintains active affiliations with

More news about: The Inner Circle


Jun 18, 2026, 10:00 ET SightMD PA Recognized with Multiple Honors in Republican Herald Readers' Choice Awards

www.sightmd.com or call 800.823.5530.SightMD Pennsylvania is actively seeking ophthalmology professionals who are interested in joining its outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact the Chief Medical Officer,

More news about: SightMD


Jun 18, 2026, 09:00 ET ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing

[email protected] for the press:Frank SmithHead of Global CommunicationsOphthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]

More news about: Carl Zeiss Meditec AG


Jun 18, 2026, 09:00 ET ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing

[email protected] for the press:Frank SmithHead of Global CommunicationsOphthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]

More news about: Carl Zeiss Meditec AG


Jun 16, 2026, 11:21 ET Global Auto Keratometer Market: Growth, Demand & Innovation | From US$ 7.4 Bn to US$ 11.1 Bn: Market Expansion Story | Persistence Market Research

is creating strong demand for auto keratometers as governments and healthcare systems expand vision screening programs. According to the WHO and ophthalmology studies, approximately 2.6 billion people are currently affected by myopia globally, and prevalence continues to rise rapidly among children and

More news about: Persistence Market Research Pvt. Ltd.


Jun 16, 2026, 09:30 ET Clínica de Especialidades Oftalmológicas (CEO) Becomes First Organization in the World Accredited Under GHA Healthcare Organization Standards 1.0 and GHA Integrated Accreditation for Medical Travel

patients and families they serve."Founded 18 years ago, Clínica de Especialidades Oftalmológicas CEO has established itself as a leading ophthalmology provider in Colombia. The organization is supported by a team of 57 ophthalmologists and performs approximately 1,000 surgical procedures per month.

More news about: Global Healthcare Accreditation


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.